Department of Health and Social Care

Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.

The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.

The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.

Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.

The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.

Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.

The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.

The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.

Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.

The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.

The Public Health Grant supports local authorities to deliver vital public health services that focus on reducing preventable illnesses through services such as smoking cessation, drug and alcohol addiction treatment and recovery, health visiting, and sexual health clinics. Public Health Grant allocations are weighted heavily towards deprivation, with per capita funding for the most deprived local authority more than two times greater than that for the least deprived.

More than £13.4 billion will be consolidated into the Public Health Grant to local authorities, and a retained business rates arrangement with Greater Manchester local authorities, over the next three years beginning in 2026/27. This is a 5.6% total cash increase over the period, on top of 5.5% cash growth in 2025/26.

The National Health Service also funds important public health services, including national screening and immunisation programmes. In doing so, NHS England has regard to the need to reduce inequalities both in access to services and in health outcomes.

The National Health Service and local government provide a range of obesity services, from universal prevention initiatives to targeted interventions, including behaviour change programmes, digital tools and apps, and specialist services for people living with severe obesity and related conditions. These services support individuals at every stage to achieve and maintain a healthier weight.

Commissioning and funding decisions for obesity services are made locally by local authorities and NHS organisations in line with assessed population needs and available budgets. The Department works with these partners and NHS England to provide national policy direction, to support effective and sustainable service models and to introduce digital behavioural programmes.

NHS England is supporting integrated care boards (ICBs) to deliver a phased roll‑out of tirzepatide for the treatment of obesity. They have provided funding and guidance to ICBs and established a national wraparound support service for patients receiving these treatments, covering diet, physical activity, and behaviour change.

As set out in our 10-Year Health Plan for England, we are taking decisive action on the obesity crisis, including restricting junk food advertising to children, and setting healthy sales reporting and targets for large food businesses.

Whilst we recognise that prevention will always be better than a cure, we also need to support those already living with obesity. We have committed to doubling the number of people able to access the NHS Digital Weight Management Programme and to expand access to the newest obesity medicines.

In 2025/26, total forecast mental health spend is £15.6 billion, which works out at 8.71% of the recurrent National Health Service baseline of £179.4 billion. This was set out in a Written Ministerial Statement by my Rt Hon. Friend, the Secretary of State for Health and Social Care, on 27 March 2025.

As the Medium-Term Planning Framework makes clear, we need a new approach for mental health to drive down waits, improve the quality of care, and increase the productivity of mental health services.

Funding is a key part of this. We have set out that over the next three years, integrated care boards will be required to meet the mental health investment standard by protecting mental health spending in real terms. In other words, rising in line with inflation from 2026/27.

The Department funds research into mental health via the National Institute for Health and Care Research (NIHR). Through the NIHR, the Department is investigating a wide range of factors that contribute to the increase in mental health prevalence across England, including social, environmental, demographic, and biological factors. The Department also funds several population surveys that measure the national prevalence of mental health disorders.

The Department recently launched an independent review led by Professor Peter Fonagy into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism. This review will examine the evidence on rising demand for mental health, autism, and ADHD services so people receive the right support at the right time and in the right place. The review will produce a short report setting out conclusions and recommendations for responding to the rising need, both within the Government and across the health system and wider public services.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.

NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.

NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy.

In 2021, the MHRA published a Public Assessment Report (PAR), reviewing the available evidence for topical steroid withdrawal (TSW) reactions, which can be found at the following link:

https://www.gov.uk/government/publications/topical-steroid-withdrawal-reactions-a-review-of-the-evidence

To inform this report, a comprehensive review of the available evidence was undertaken. This included an assessment of data from Yellow Card reports to identify suspected spontaneous cases of TSW reactions associated with topical corticosteroids on the Yellow Card database, as well as information from the published literature and other medicines regulators. The review considered whether regulatory action was required to minimise the risk of these events.

The PAR resulted in two Drug Safety Updates in 2021 and 2024 which aimed to raise awareness on the risk of TSW reactions and introduce new labelling. Both updates are available, respectively, at the following two links:

https://www.gov.uk/drug-safety-update/topical-corticosteroids-information-on-the-risk-of-topical-steroid-withdrawal-reactions

https://www.gov.uk/drug-safety-update/topical-steroids-introduction-of-new-labelling-and-a-reminder-of-the-possibility-of-severe-side-effects-including-topical-steroid-withdrawal-reactions

The MHRA uses the Medical Dictionary for Regulatory Activities (MedDRA) to code suspected adverse drug reactions reported by patients and healthcare professionals via the Yellow Card scheme. MedDRA is an international, clinically validated medical terminology used by regulatory authorities and the biopharmaceutical industry throughout the entire regulatory process, from pre-marketing to post-marketing safety monitoring. MedDRA is updated twice annually, and new terms can be proposed by any MedDRA users. Following the publication of the PAR, the term “Topical steroid withdrawal reaction” was added to MedDRA as a lower level term in version 24.1 and made available to users of the Yellow Card website in February 2022 as part of routine updates. This helps to ensure that more reports pertaining to TSW reactions are appropriately captured. The MHRA continues to closely monitor Yellow Card reports submitted for suspected TSW reactions.

The MHRA continues to engage with the British Association of Dermatologist who have also released a statement, which is available at the following link:

https://cdn.bad.org.uk/uploads/2024/02/22095550/Topical-Steroid-Withdrawal-Joint-Statement.pdf

The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.

The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.

Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.

Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.

The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.

NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.

The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.

The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.

Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.

Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.

The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.

NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.

The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.

The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.

Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.

Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.

The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.

NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.

The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.

The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.

Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.

Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.

The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.

NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.

In 2019, the UK Chief Medical Officers published a commentary on the findings of a systematic review on screen-based activities and children’s mental health. They found an association between screen-based activities and mental health but could not establish causality. The commentary is avaiable in the document attached.

On 20 January 2026, the Government announced a forthcoming consultation on how to ensure children have a healthy relationship with devices, introduce rapid trials on measures to reduce screentime and limit access at night, and produce evidence-informed screentime guidance for parents of children aged five to 16 years old. This three-month consultation will be evidence-led, with input from independent experts, and will include determining the right minimum age for children to access social media. It will report in the summer.

Over the past decade, greater public awareness and reduced stigma around mental health have coincided with a rise in common mental health conditions and increased demand for National Health Service support, highlighting the need to better understand and address people’s needs.

The independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism will therefore examine a range of potential drivers of mental health conditions, the impact of clinical practice, including the role of diagnosis, opportunities for prevention and early intervention, and models of support within and beyond the NHS.

The review’s Terms of Reference are published on the GOV.UK website, in an online only format.

Research is crucial in tackling cancer, which is why the Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority.

Too little is known about how to prevent, diagnose, and manage brain tumours. They remain one of the hardest cancers to treat and a challenging area for research. That is why we are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress.

In December 2025, the NIHR announced an initial £13.7 million investment in the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. Significant further funding is due to be awarded shortly. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.

The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality. Welcoming applications on brain cancer to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.

The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours and recognises the significant impact this rare cancer can have on patients, carers, and their families. All new licensed medicines, including medicines for brain cancer, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. NICE is actively evaluating a number of new medicines for potential use in the treatment of brain cancers.

NICE works closely with companies and the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), and aims to issue guidance on new medicines as close as possible to the time of licensing. The NHS in England is legally required to fund medicines recommended by NICE and funding from the Cancer Drugs Fund is available for cancer medicines from the point of a draft positive NICE recommendation, bringing forward patient access by up to five months.

The MHRA has several pathways which facilitate rapid assessment of medicines. This includes international collaborations such as Project Orbis and the Access Consortium. The MHRA has also introduced the International Recognition Pathway, which allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners, and the Innovative Licensing and Access Pathway scheme, focussed on getting new and transformative medicines to patients in the UK health system more quickly. Recently, the MHRA also issued new regulations to make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.

No specific assessment has been made.

The intention of the reference pricing is to support long term capacity in ophthalmology by enabling trusts to reinvest realised savings directly into local services, including workforce, equipment, and service redesign. Clinical autonomy is maintained, and clinicians will continue to be able to tailor treatments to individual patient needs, including complex cases, where this is clinically indicated.

National Health Service organisations must ensure that all patients have equitable access to care, and that decisions or policies do not unfairly disadvantage people or lead to an increase in inequalities. All NHS organisations are legally obliged to not discriminate.

This means that although we promote digital first services to those who choose to use them, a non-digital solution should be available for those patients who cannot or do not wish to engage digitally to ensure continued, equitable access to care.

These non-digital routes must be available for all services provided by NHS organisations.

We are working to improve access to digital services, outcomes, and experiences for the widest range of people, based on their preferences. Digital health tools should be part of a wider offering that includes face-to-face support with appropriate help for people who struggle to access digital services.

In April 2025, the statutory gambling levy came into effect to fund the research, prevention, and treatment of gambling-related harm across Great Britain. In its first year, the levy has raised nearly £120 million, with 30% allocated to gambling harms prevention activity.

The Department for Culture, Media and Sport, which is responsible for the implementation and oversight of the gambling levy, remains confident that levy commissioners are best placed to make decisions on the future of their work programmes regarding the research, prevention, and treatment of gambling-related harms.

As prevention commissioners, the Office for Health Improvement and Disparities (OHID) in England and the Scottish and Welsh administrations continue to work collaboratively on the development of their respective work programmes, drawing on expertise from across the system. OHID will employ a ‘test and learn’ approach as they transition to the new levy system, to better-understand what interventions are most effective in preventing gambling harms at a local, regional, and national level.

Local authorities are well placed to play a central role in preventing gambling‑related harms across local communities. An OHID-led stocktake of local authority activity in this space indicated that whilst some activity is already underway, there is appetite within local authorities to do more.

OHID are developing a fund for all upper-tier local authorities across England, which will aim to strengthen local capacity to tackle gambling‑related harm by facilitating improved understanding of local need and supporting the development of effective local and regional networks. This will be delivered alongside the Gambling Harms Prevention: Voluntary, Community and Social Enterprise grant fund which launched in January to fund voluntary, community, and social enterprise organisations to deliver prevention activity across England until March 2028. Further information on the Gambling Harms Prevention: Voluntary, Community and Social Enterprise grant fund is avaiable at the following link:

https://find-government-grants.service.gov.uk/grants/gambling-harms-prevention-voluntary-community-and-social-enterprise-vcse-grant-fund-1

The UK Rare Diseases Framework was published following the National Conversation on Rare Diseases, which received nearly 6,300 responses. This helped identify the four priorities of the framework in tackling rare diseases: helping patients get a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatment, and drugs.

The Government remains committed to improving the lives of those living with rare conditions, and will be publishing the next England Rare Diseases Action Plan to update on these priorities as in previous years. The evaluation of England’s action plans is expected to complete in May 2026. We recognise that despite the progress that has been made there remains considerable unmet need for people living with rare conditions. Ministers from all four nations have agreed to extend the UK Rare Diseases Framework by one year to January 2027, recognising the continued relevance of its four priorities, including improving access to specialist care, treatment, and drugs. We will engage with the rare diseases community to help shape the next steps.

NHS England has made good progress in growing and developing the cancer and diagnostics workforce.

In 2024/25, approximately 8,000 people received training to either enter the cancer and diagnostics workforce or develop in their roles. As part of this, over 1,600 people were on apprenticeship courses, with over 270 additional medical specialty training places funded. Over 1,000 clinical nurse specialist (CNS) grants were made available to new and aspiring CNSs across England, including Devon.

We are working to end the postcode lottery for cancer services. NHS England is working with NHS regions and the royal colleges to increase the number of clinical and medical oncology staff overall. In addition, we aim to fill vacancies and expand workforces in trusts that most need more staff, including in rural and coastal areas, to help boost performance.

Residents of Bletchley who access oncology care would most likely attend Milton Keynes University Hospital which offers on-site chemotherapy and radiotherapy, the latter led by the Oxford University Hospitals NHS Foundation Trust. Workforce reviews are currently under way to ensure that this trust can accommodate increasing demand for services and to ensure that residents can access new treatments when they become available.

The National Cancer Plan, which will be published shortly, will highlight how we will reform our workforce to improve cancer patient outcomes, including for those patients in the Buckingham and Bletchley constituency. We will ensure that we have the right staff, in the right places, with the right skills, so patients can access quality care when and where they need it.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department does not process personal health information. This type of information is handled by NHS England and other authorised health bodies.

We work closely with NHS England to ensure that any technology used across the health system meets the legal and ethical standards required for safeguarding personal health data. This includes data protection, information governance, and the safeguards required for handling health data. These checks ensure that any system we bring into use aligns with the rules that protect people’s privacy.

When personal data is processed as part of specific programmes, it is handled by approved delivery partners under strict governance arrangements. These partners act only on behalf of the Department and in line with data protection law and contractual controls.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has had no such discussions.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has regular discussions on a wide range of matters, including with trusts and integrated care boards (ICBs).

The Government has recognised that, nationally, demand for assessments for neurodevelopmental conditions such as autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.

It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, including access to neurodevelopmental assessments.

Through the Medium-term planning framework, published 24 October, NHS England has set clear expectations for local ICBs and trusts to improve access, experience, and outcomes for autism and ADHD services over the next three years, focusing on improving quality and productivity.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

Care agencies who carry out a regulated activity must be registered by the Care Quality Commission (CQC) and are expected to comply with relevant regulations. Where a care agency does not carry out a regulated activity but supplies workers to a regulated care provider, the legal duty to comply with CQC regulations sits with the registered provider using the agency and the registered manager.

Regulation 19 of the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 sets out that it is the responsibility of the regulated provider to ensure robust and safe recruitment practices are in place, and to make sure that all staff, including agency staff, are suitably experienced, competent, and able to carry out their role. Further information on Regulation 19 is avaiable at the following link:

https://www.cqc.org.uk/guidance-regulation/providers/regulations-service-providers-and-managers/health-social-care-act/regulation-19

Registered providers are also expected to comply with Regulation 18: Staffing, which sets out a provider’s responsibility to deploy enough suitably qualified, competent, and experienced staff. Further information on Regulation 18 is avaiable at the following link:

https://www.cqc.org.uk/guidance-regulation/providers/regulations-service-providers-and-managers/health-social-care-act/regulation-18

The CQC can assess compliance with these regulations through assessment and monitoring activity. Where a breach of regulation or non-compliance is identified, the CQC can take regulatory action.

An Enhanced Disclosure and Barring Service (DBS) check must be undertaken prior to the recruitment of all care workers. In line with the CQC guidance for DBS checks, staff working with vulnerable adults can only start work before a DBS certificate is received if they have had a DBS Adult First Check, are appropriately supervised, and do not escort people away from the premises unless accompanied by someone with a DBS check.

Whilst the majority of palliative care and end-of-life care is provided by National Health Service staff and services, we recognise the vital part that voluntary sector organisations, including hospices, also play in providing support to people at the end of life and their loved ones.

Integrated care boards (ICBs) are responsible for commissioning palliative care and end-of-life care services that meet the needs of their local populations. To support ICBs in this duty, NHS England has published statutory guidance and service specifications. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations, which can include hospice services available within the ICB catchment.

NHS England has reinforced the requirement that, from April 2026, ICBs and relevant providers must have a full understanding of current and projected service utilisation and costs, including for those needing end-of-life care, to support sustainable planning. This will help systems to better assess local need and maintain quality of care.

The Government is also providing £125 million of capital funding for eligible adult, and children and young people’s hospices and we recently also confirmed approximately £80 million of revenue funding for the next three years for children and young people’s hospices in England.

Additionally, the Government is developing a Palliative Care and End-of-Life Care Modern Service Framework (MSF) for England. It will drive improvements in access, quality, and sustainability, and support ICB to commission high-quality, personalised care. Through our MSF, we will closely monitor the shift towards the strategic commissioning of palliative care and end-of-life care services, and we will also consider contracting and commissioning arrangements.

I refer the hon. Member to the answer I gave on 29 January 2026 to Question 99357.

In 2019, the UK Chief Medical Officers published a commentary on a systematic review of screen-based activities, including social media, and their impact on children and young people’s mental health. They found an association between screen-based activities and mental health but could not establish causality.

The Department of Health and Social Care and the Department of Education are jointly working to produce and publish new practical, evidence informed guidance on screentime for early years (zero to five) by April 2026. An expert group of child health and development specialists has been convened to shape the guidance, which will also be informed by the perspectives of parents and carers.

On 20 January 2026, the Government announced a forthcoming consultation on how to ensure children have a healthy relationship with devices, introduce rapid trials on measures to reduce screentime and limit access at night, and produce evidence-informed screentime guidance for parents of children aged between five and sixteen years old. This three-month consultation will be evidence-led, with input from independent experts. It will report in the summer.

Everyone who has been harmed from sodium valproate has our deepest sympathies.

Action has been taken to minimise the risk associated with valproate to women with epilepsy, and their families. This includes the valproate Pregnancy Prevention Programme, which ensures that women and girls taking valproate understand the potential risks should they become pregnant, are using effective contraception, and are regularly monitored. Further measures introduced in 2024 mean valproate must not be started in new patients, either male or female, younger than 55 years old, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.

The Government is also carefully considering the Patient Safety Commissioner’s recommendations made in The Hughes Report, which includes proposed approaches to redress for those harmed by sodium valproate. This work requires coordinated input from several departments, and we will provide a further update in due course.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population.

Children with developmental coordination disorder, commonly known as dyspraxia, access support through local National Health Service occupational therapy, paediatrics, physiotherapy, and educational services.

NHS guidance sets out a referral process which typically begins with a general practitioner, health visitor, or a Special Educational Needs Coordinator, who may refer the child to paediatric occupational therapy and physiotherapist for assessment and support. The NHS guidance is available at the following link:

https://www.nhs.uk/conditions/developmental-coordination-disorder-dyspraxia/

For the first time, we have set a target for systems to work to reduce long waits for community health services. By 2028/29 at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care.

Surrey Health provides occupational therapy support for children with dyspraxia of all ages. They provide speech and language therapy support for children under five years old who have verbal dyspraxia and a school aged speech and language therapy service for children over five years old.

Referrals for continence, occupational therapy, speech and language therapy and physiotherapy can be made directly by parents/carers as well as the child’s health visitor, general practitioner, therapist, early years’ service, hospital paediatricians, audiology service, Mindworks Surrey, and other agencies.

This is for speech and language therapy support for those under five years old, and therefore not in a school setting, and for occupational therapy of all ages. If a child is in school and requires speech and language therapy, the referral is through the school as the service is a school-based service.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population.

Children with developmental coordination disorder, commonly known as dyspraxia, access support through local National Health Service occupational therapy, paediatrics, physiotherapy, and educational services.

NHS guidance sets out a referral process which typically begins with a general practitioner, health visitor, or a Special Educational Needs Coordinator, who may refer the child to paediatric occupational therapy and physiotherapist for assessment and support. The NHS guidance is available at the following link:

https://www.nhs.uk/conditions/developmental-coordination-disorder-dyspraxia/

For the first time, we have set a target for systems to work to reduce long waits for community health services. By 2028/29 at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care.

Surrey Health provides occupational therapy support for children with dyspraxia of all ages. They provide speech and language therapy support for children under five years old who have verbal dyspraxia and a school aged speech and language therapy service for children over five years old.

Referrals for continence, occupational therapy, speech and language therapy and physiotherapy can be made directly by parents/carers as well as the child’s health visitor, general practitioner, therapist, early years’ service, hospital paediatricians, audiology service, Mindworks Surrey, and other agencies.

This is for speech and language therapy support for those under five years old, and therefore not in a school setting, and for occupational therapy of all ages. If a child is in school and requires speech and language therapy, the referral is through the school as the service is a school-based service.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population.

Children with developmental coordination disorder, commonly known as dyspraxia, access support through local National Health Service occupational therapy, paediatrics, physiotherapy, and educational services.

NHS guidance sets out a referral process which typically begins with a general practitioner, health visitor, or a Special Educational Needs Coordinator, who may refer the child to paediatric occupational therapy and physiotherapist for assessment and support. The NHS guidance is available at the following link:

https://www.nhs.uk/conditions/developmental-coordination-disorder-dyspraxia/

For the first time, we have set a target for systems to work to reduce long waits for community health services. By 2028/29 at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care.

Surrey Health provides occupational therapy support for children with dyspraxia of all ages. They provide speech and language therapy support for children under five years old who have verbal dyspraxia and a school aged speech and language therapy service for children over five years old.

Referrals for continence, occupational therapy, speech and language therapy and physiotherapy can be made directly by parents/carers as well as the child’s health visitor, general practitioner, therapist, early years’ service, hospital paediatricians, audiology service, Mindworks Surrey, and other agencies.

This is for speech and language therapy support for those under five years old, and therefore not in a school setting, and for occupational therapy of all ages. If a child is in school and requires speech and language therapy, the referral is through the school as the service is a school-based service.

The Department has not to date undertaken any formal assessment or evaluation of the potential impact of the use of artificial intelligence (AI) to predict levels of demand in accident and emergency departments on waiting times, or staff workload, wellbeing, or retention.

Decisions regarding the adoption and deployment of AI tools, including those used for demand prediction in accident and emergency settings as discussed in the article ‘Faster treatments and support for health workers as AI tackles accident and emergency bottlenecks’, are made at a local level by individual National Health Service trusts. At present, NHS trusts have the autonomy to determine the use of such technologies, taking into account the needs and priorities of their respective organisation, and should evaluate and review the impact of AI deployment within their care settings.

The Department has not to date undertaken any formal assessment or evaluation of the potential impact of the use of artificial intelligence (AI) to predict levels of demand in accident and emergency departments on waiting times, or staff workload, wellbeing, or retention.

Decisions regarding the adoption and deployment of AI tools, including those used for demand prediction in accident and emergency settings as discussed in the article ‘Faster treatments and support for health workers as AI tackles accident and emergency bottlenecks’, are made at a local level by individual National Health Service trusts. At present, NHS trusts have the autonomy to determine the use of such technologies, taking into account the needs and priorities of their respective organisation, and should evaluate and review the impact of AI deployment within their care settings.

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including the potential impact of kidney disease on mental health.

These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on the impact of kidney disease on mental health to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.

In the past five financial years, the NIHR has allocated £2.051 million in new direct research funding to six projects related to kidney disease, in which the psychosocial aspects of living with or undergoing treatment or testing for kidney disease were addressed as part of the research.

Details of NIHR funding allocated to individual research awards are openly published and updated quarterly on the ‘Open Data’ site of the NIHR website, at the following link:

https://nihr.opendatasoft.com/explore/

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including the potential impact of kidney disease on mental health.

These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on the impact of kidney disease on mental health to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.

In the past five financial years, the NIHR has allocated £2.051 million in new direct research funding to six projects related to kidney disease, in which the psychosocial aspects of living with or undergoing treatment or testing for kidney disease were addressed as part of the research.

Details of NIHR funding allocated to individual research awards are openly published and updated quarterly on the ‘Open Data’ site of the NIHR website, at the following link:

https://nihr.opendatasoft.com/explore/